Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study
NCT02760615 · Takeda · PHASE4 · withdrawn · last registry update 2020-10-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No enrollment” | – | Registry record, Takeda |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ADORA1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-09-17Phase 3 first posted: University of Florida, Ticagrelor + Aspirin + Rivaroxaban + Aspirin (NCT05047172)
- 2021-05-11Results posted on the registry: Dana-Farber Cancer Institute, T-DM1 + Pertuzumab (NCT02326974)
- 2021-05-05Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Trastuzumab Emtansine (NCT04873362)
- 2021-02-05Results posted on the registry: National Cancer Institute (NCI), Trastuzumab Emtansine (NCT04439110)
- 2021-01-13Phase 3 first posted: M.D. Anderson Cancer Center, Busulfan + Cladribine (NCT04708054)
- 2021-01-05Phase 3 first posted: Queen Mary University of London, Cladribine (MAVENCLAD®) + Placebo (NCT04695080)
- 2020-11-09Phase 3 first posted: Daiichi Sankyo, DS-8201a + T-DM1 (NCT04622319)
- 2020-10-28Phase 3 first posted: Jennifer Holder-Murray, Neuraxial Analgesia + Regional Block 1: Paravertebral (NCT04606264)
- 2020-09-30Phase 3 first posted: University Hospital, Lille, Caffeine + Placebo (NCT04570085)
- 2020-07-07Phase 3 first posted: Alliance for Clinical Trials in Oncology, Trastuzumab Emtansine + Placebo Administration (NCT04457596)
- 2020-02-11Phase 3 first posted: Oklahoma Medical Research Foundation, Metformin + Placebo oral tablet (NCT04264897)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision